Piper Sandler Posts 22x Forward P/E as Biotech Funding Recovers
Piper Sandler’s advisory and corporate financing segments are outperforming thanks to a recovery in biotech funding, robust M&A activity, and a mid-market private equity resurgence. The firm trades at 22x forward P/E, cheaper than Evercore’s 26x but pricier than Lazard’s sub-20x valuation.
1. Leadership Appointments Strengthen Sector Coverage
Piper Sandler has elevated Brandon Rice and Chad Huber to co-heads of Healthcare Investment Banking alongside existing co-head Peter Day, reflecting sustained growth in the firm’s life sciences advisory and capital markets activity. Rice brings deep M&A advisory and equity issuance experience from his role as managing director, having executed over a dozen transactions for disruptive med-tech firms in the past two years. Huber transitions from global co-head of Equity Capital Markets, where he originated equity financings totaling more than $1.5 billion for biotech and pharma clients. In Consumer Investment Banking, the firm adds Carlos Sanchez as co-head alongside Damon Chandik and Janica Lane; Sanchez has led M&A mandates across food & beverage and specialty retail, advising on deals representing aggregate enterprise values exceeding $4 billion last year. Finally, Paul Scansaroli will serve as global co-head of Equity Capital Markets with David Stadinski, leveraging his track record of over 30 completed equity transactions for high-growth healthcare companies and their venture investors. These leadership moves aim to scale Piper Sandler’s advisory platform and deepen client relationships across fast-growing industry verticals.
2. Biotech Funding Recovery Boosts Advisory and ECM Pipelines
Piper Sandler’s advisory and corporate finance segments are benefiting from an uptick in biotech capital formation and mid-market private equity deal flow. Healthcare ECM deal volume increased by 40% year-over-year in the first quarter, driven by follow-on offerings and SPAC mergers for life sciences companies. The firm’s bankers have advised on more than ten transactions in the sector since January, including three significant crossover financings exceeding $200 million apiece. On the M&A front, Piper Sandler completed five announced life sciences deals with combined enterprise values of nearly $3 billion, positioning the bank as a top-five advisor in the $100 million to $500 million segment. With DCM activity stabilizing under lower interest rate conditions, Piper Sandler’s integrated model is capturing a growing share of healthcare issuance while sustaining strong margins in its advisory business.